155 related articles for article (PubMed ID: 11208636)
1. Health status deterioration in patients with chronic obstructive pulmonary disease.
Spencer S; Calverley PM; Sherwood Burge P; Jones PW;
Am J Respir Crit Care Med; 2001 Jan; 163(1):122-8. PubMed ID: 11208636
[TBL] [Abstract][Full Text] [Related]
2. American translation, modification, and validation of the St. George's Respiratory Questionnaire.
Barr JT; Schumacher GE; Freeman S; LeMoine M; Bakst AW; Jones PW
Clin Ther; 2000 Sep; 22(9):1121-45. PubMed ID: 11048909
[TBL] [Abstract][Full Text] [Related]
3. Stages of disease severity and factors that affect the health status of patients with chronic obstructive pulmonary disease.
Hajiro T; Nishimura K; Tsukino M; Ikeda A; Oga T
Respir Med; 2000 Sep; 94(9):841-6. PubMed ID: 11001074
[TBL] [Abstract][Full Text] [Related]
4. A novel, short, and simple questionnaire to measure health-related quality of life in patients with chronic obstructive pulmonary disease.
Hajiro T; Nishimura K; Jones PW; Tsukino M; Ikeda A; Koyama H; Izumi T
Am J Respir Crit Care Med; 1999 Jun; 159(6):1874-8. PubMed ID: 10351933
[TBL] [Abstract][Full Text] [Related]
5. Efficacy and tolerability of indacaterol 75 μg once daily in patients aged ≥40 years with chronic obstructive pulmonary disease: results from 2 double-blind, placebo-controlled 12-week studies.
Kerwin EM; Gotfried MH; Lawrence D; Lassen C; Kramer B
Clin Ther; 2011 Dec; 33(12):1974-84. PubMed ID: 22177371
[TBL] [Abstract][Full Text] [Related]
6. Quality of life changes in COPD patients treated with salmeterol.
Jones PW; Bosh TK
Am J Respir Crit Care Med; 1997 Apr; 155(4):1283-9. PubMed ID: 9105068
[TBL] [Abstract][Full Text] [Related]
7. Comparison of discriminative properties among disease-specific questionnaires for measuring health-related quality of life in patients with chronic obstructive pulmonary disease.
Hajiro T; Nishimura K; Tsukino M; Ikeda A; Koyama H; Izumi T
Am J Respir Crit Care Med; 1998 Mar; 157(3 Pt 1):785-90. PubMed ID: 9517591
[TBL] [Abstract][Full Text] [Related]
8. Impact of preventing exacerbations on deterioration of health status in COPD.
Spencer S; Calverley PM; Burge PS; Jones PW
Eur Respir J; 2004 May; 23(5):698-702. PubMed ID: 15176682
[TBL] [Abstract][Full Text] [Related]
9. Nebulized arformoterol in patients with COPD: a 12-week, multicenter, randomized, double-blind, double-dummy, placebo- and active-controlled trial.
Baumgartner RA; Hanania NA; Calhoun WJ; Sahn SA; Sciarappa K; Hanrahan JP
Clin Ther; 2007 Feb; 29(2):261-78. PubMed ID: 17472819
[TBL] [Abstract][Full Text] [Related]
10. Airway inflammation contributes to health status in COPD: a cross-sectional study.
Snoeck-Stroband JB; Postma DS; Lapperre TS; Gosman MM; Thiadens HA; Kauffman HF; Sont JK; Jansen DF; Sterk PJ
Respir Res; 2006 Nov; 7(1):140. PubMed ID: 17137518
[TBL] [Abstract][Full Text] [Related]
11. Identifying COPD patients at increased risk of mortality: predictive value of clinical study baseline data.
Halpin DM; Peterson S; Larsson TP; Calverley PM
Respir Med; 2008 Nov; 102(11):1615-24. PubMed ID: 18691861
[TBL] [Abstract][Full Text] [Related]
12. Effect of exacerbation on quality of life in patients with chronic obstructive pulmonary disease.
Seemungal TA; Donaldson GC; Paul EA; Bestall JC; Jeffries DJ; Wedzicha JA
Am J Respir Crit Care Med; 1998 May; 157(5 Pt 1):1418-22. PubMed ID: 9603117
[TBL] [Abstract][Full Text] [Related]
13. On the role of abnormal DL(CO) in ex-smokers without airflow limitation: symptoms, exercise capacity and hyperpolarised helium-3 MRI.
Kirby M; Owrangi A; Svenningsen S; Wheatley A; Coxson HO; Paterson NA; McCormack DG; Parraga G
Thorax; 2013 Aug; 68(8):752-9. PubMed ID: 23604381
[TBL] [Abstract][Full Text] [Related]
14. Safety and efficacy of the once-daily anticholinergic BEA2180 compared with tiotropium in patients with COPD.
Abrahams R; Moroni-Zentgraf P; Ramsdell J; Schmidt H; Joseph E; Karpel J
Respir Med; 2013 Jun; 107(6):854-62. PubMed ID: 23490224
[TBL] [Abstract][Full Text] [Related]
15. Changes in lung function and health status in patients with COPD treated with tiotropium or salmeterol plus fluticasone.
Kurashima K; Hara K; Yoneda K; Kanauchi T; Kagiyama N; Tokunaga D; Takayanagi N; Ubukata M; Sugita Y
Respirology; 2009 Mar; 14(2):239-44. PubMed ID: 19210650
[TBL] [Abstract][Full Text] [Related]
16. The cross-sectional and longitudinal association of the BODE index with quality of life in patients with chronic obstructive pulmonary disease.
Lin YX; Xu WN; Liang LR; Pang BS; Nie XH; Zhang J; Wang H; Liu YX; Wang DQ; Xu ZY; Wang HW; Zhang HS; He ZY; Yang T; Wang C
Chin Med J (Engl); 2009 Dec; 122(24):2939-44. PubMed ID: 20137478
[TBL] [Abstract][Full Text] [Related]
17. Validity of St. George's Respiratory Questionnaire for Greek patients with chronic obstructive pulmonary disease.
Katsoulas TA; Skordilis EK; Myrianthefs P; Fildisis G; Theodosopoulou E; Baltopoulos G
Percept Mot Skills; 2010 Jun; 110(3 Pt 1):772-88. PubMed ID: 20681331
[TBL] [Abstract][Full Text] [Related]
18. Withdrawal of fluticasone propionate from combined salmeterol/fluticasone treatment in patients with COPD causes immediate and sustained disease deterioration: a randomised controlled trial.
Wouters EF; Postma DS; Fokkens B; Hop WC; Prins J; Kuipers AF; Pasma HR; Hensing CA; Creutzberg EC;
Thorax; 2005 Jun; 60(6):480-7. PubMed ID: 15923248
[TBL] [Abstract][Full Text] [Related]
19. Methacholine reactivity predicts changes in lung function over time in smokers with early chronic obstructive pulmonary disease. The Lung Health Study Research Group.
Tashkin DP; Altose MD; Connett JE; Kanner RE; Lee WW; Wise RA
Am J Respir Crit Care Med; 1996 Jun; 153(6 Pt 1):1802-11. PubMed ID: 8665038
[TBL] [Abstract][Full Text] [Related]
20. [Correlation among the levels of C-reactive protein and interleukin-18, quality of life, and lung function in patients with chronic obstructive pulmonary disease].
Long H; Luo H; Chen P; Li Y
Zhong Nan Da Xue Xue Bao Yi Xue Ban; 2011 Nov; 36(11):1090-6. PubMed ID: 22169727
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
